S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   444.21 (-0.14%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   444.21 (-0.14%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   444.21 (-0.14%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   444.21 (-0.14%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)

AVITA Medical (RCEL) Stock Price, News & Analysis

$16.08
-0.42 (-2.55%)
(As of 02:10 PM ET)
Today's Range
$15.82
$16.65
50-Day Range
$13.91
$18.31
52-Week Range
$9.16
$21.70
Volume
60,751 shs
Average Volume
165,931 shs
Market Capitalization
$413.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.80

AVITA Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
69.2% Upside
$27.80 Price Target
Short Interest
Healthy
2.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.15) to ($0.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.81 out of 5 stars

Medical Sector

817th out of 939 stocks

Surgical & Medical Instruments Industry

87th out of 98 stocks

RCEL stock logo

About AVITA Medical Stock (NASDAQ:RCEL)

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

RCEL Stock Price History

RCEL Stock News Headlines

RCEL Oct 2024 17.500 put
RCEL Apr 2024 22.500 put
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
BRIEF-Seatrium Limited Says FY Revenue S$7.3 Bln
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical Q4 2023 Earnings Preview
RCEL Mar 2024 15.000 call
AVITA Medical: Q3 Earnings Insights
See More Headlines
Receive RCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVITA Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:RCEL
Fax
N/A
Employees
207
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$27.80
High Stock Price Target
$40.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+68.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-35,380,000.00
Pretax Margin
-70.43%

Debt

Sales & Book Value

Annual Sales
$50.14 million
Book Value
$1.92 per share

Miscellaneous

Free Float
25,203,000
Market Cap
$424.22 million
Optionable
Optionable
Beta
1.39

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. James M. Corbett (Age 66)
    CEO, President & Executive Director
    Comp: $1.16M
  • Mr. David O'Toole (Age 65)
    Chief Financial Officer
    Comp: $574.64k
  • Ms. Donna Shiroma (Age 61)
    General Counsel, Chief Compliance Officer & Secretary
    Comp: $688.6k
  • Mr. David Fencil
    Senior Vice President of Global Operations
  • Dr. Katie Bush Ph.D.
    Senior Vice President of Scientific & Medical Affairs
  • Ms. Jessica Ekeberg
    Investor Relations Executive
  • Ms. Debbie Garner
    Senior Vice President of Global Marketing & Strategy
  • Mr. Rob Hall
    Senior Vice President of Human Resources
  • Mr. Terry Bromley
    Senior Vice President of Global Sales
  • Dr. Niraj Doshi J.D.
    P.M.P., Ph.D., Senior Vice President of Product Development & Program Management

RCEL Stock Analysis - Frequently Asked Questions

Should I buy or sell AVITA Medical stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AVITA Medical in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RCEL shares.
View RCEL analyst ratings
or view top-rated stocks.

What is AVITA Medical's stock price target for 2024?

5 Wall Street analysts have issued 1-year price objectives for AVITA Medical's shares. Their RCEL share price targets range from $21.00 to $40.00. On average, they anticipate the company's stock price to reach $27.80 in the next twelve months. This suggests a possible upside of 69.2% from the stock's current price.
View analysts price targets for RCEL
or view top-rated stocks among Wall Street analysts.

How have RCEL shares performed in 2024?

AVITA Medical's stock was trading at $13.72 at the beginning of 2024. Since then, RCEL stock has increased by 19.8% and is now trading at $16.43.
View the best growth stocks for 2024 here
.

When is AVITA Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our RCEL earnings forecast
.

How were AVITA Medical's earnings last quarter?

AVITA Medical, Inc. (NASDAQ:RCEL) released its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.06. The company earned $14.20 million during the quarter, compared to the consensus estimate of $14.10 million. AVITA Medical had a negative net margin of 70.56% and a negative trailing twelve-month return on equity of 54.80%.

What guidance has AVITA Medical issued on next quarter's earnings?

AVITA Medical updated its first quarter 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $14.8 million-$15.6 million, compared to the consensus revenue estimate of $15.8 million.

What other stocks do shareholders of AVITA Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVITA Medical investors own include NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), PayPal (PYPL), Twilio (TWLO), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Livongo Health (LVGO).

Who are AVITA Medical's major shareholders?

AVITA Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.45%), Vanguard Group Inc. (5.42%), Pura Vida Investments LLC (1.41%), Northern Trust Corp (0.88%), Dimensional Fund Advisors LP (0.37%) and 1492 Capital Management LLC (0.28%). Insiders that own company stock include David D O'toole, Donna Shiroma, James Corbett, Jeremy Curnock Cook, Michael S Perry, Michael S Perry and Suzanne Crowe.
View institutional ownership trends
.

How do I buy shares of AVITA Medical?

Shares of RCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RCEL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners